Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
In October, we established a position in Indivior after the company reduced its sales forecast for Sublocade, a long-acting buprenorphine drug for the treatment of opioid addiction. Management lowered sales...
— Andrew Summers
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Indivior
No other institutional pitches found for this ticker yet.
More institutional theses from Summers Value Fund
UFP Technologies continued its outstanding run in 2024, bolstered by acquisitions and a growing relationship with Intuitive Surgical. The manager trimmed...
Electromed delivered record-breaking sales, earnings, and cash generation under a new leadership team, causing the stock to soar by 176%. The company's SmartVest...
Zimvie underperformed due to false acquisition rumors and execution struggles post-spin-off, but remains cheap at 1x EV/Sales. The successful divestiture...